T1	p 93 132	advanced epithelial ovarian carcinoma .
T2	p 214 224	previously
T3	p 234 245	multicentre
T4	p 296 394	patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen .
T5	p 416 464	Patients with bidimensionally measurable disease
T6	p 601 637	Patients were eligible for treatment
T7	p 932 954	dyspnea , constipation
T8	p 959 971	insomnia ) .
T9	p 988 1031	of 226 patients were evaluable for response
T10	p 1230 1231	<
T11	p 1311 1312	<
T12	p 1370 1394	years post-randomisation
T13	p 1459 1460	<
T14	p 1541 1542	<
T15	p 1920 1929	topotecan
T16	p 1944 1960	ovarian cancer .
T17	i 62 89	topotecan versus paclitaxel
T18	i 265 292	topotecan versus paclitaxel
T19	i 484 493	topotecan
T20	i 496 499	1.5
T21	i 507 515	2 ) /day
T22	i 527 548	) or paclitaxel ( 175
T23	i 556 564	2 ) /day
T24	i 574 584	infusion )
T25	i 647 664	alternate therapy
T26	i 1162 1171	topotecan
T27	i 1279 1296	paclitaxel , 14.7
T28	i 1420 1429	topotecan
T29	i 1509 1526	paclitaxel , 53.0
T30	i 1605 1614	Topotecan
T31	i 1676 1686	paclitaxel
T32	i 1920 1929	topotecan
T33	o 6 24	Long-term survival
T34	o 177 185	survival
T35	o 685 710	European Organisation for
T36	o 737 792	Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire
T37	o 824 832	symptoms
T38	o 870 969	pain , anorexia , diarrhoea , fatigue , nausea and vomiting , dyspnea , constipation and insomnia )
T39	o 1046 1061	characteristics
T40	o 1125 1151	EORTC QOL-30 questionnaire
T41	o 1180 1206	median time to progression
T42	o 1397 1412	median survival
T43	o 1651 1663	efficacy and
T44	o 1703 1775	and non-cumulative haematological toxicity . Non-haematological toxicity
T45	o 1817 1840	long-term survival rate